SEATTLE - Atossa Therapeutics, Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company specializing in oncology treatments, particularly for breast cancer, announced the immediate appointment of Dr. Tessa Cigler to its board of directors on Monday. Dr. Cigler, a medical oncologist and clinical investigator at the Weill Cornell Breast Center in New York City, brings extensive experience in patient care and clinical trials to the company.
Steven Quay, M.D., Ph.D., President and CEO of Atossa, expressed his pleasure in welcoming Dr. Cigler, highlighting her firsthand knowledge of the urgent need for more effective and tolerable breast cancer treatments. Dr. Cigler's appointment is expected to bolster the company's ongoing development of (Z)-endoxifen, an agent currently in four Phase 2 trials, with primary data from two trials anticipated in the second half of the year.
Dr. Cigler shared her enthusiasm for joining Atossa's mission to prevent and improve treatment options for breast cancer, emphasizing the potential of (Z)-endoxifen to transform patient care. Her academic credentials include an undergraduate degree from Harvard College, an M.D. from Duke University School of Medicine, and a Master's in Public Health from the Harvard School of Public Health. She completed her residency at the New York Presbyterian Hospital Weill Cornell Medical Center and a fellowship at the Dana-Farber Harvard Cancer Center.
(Z)-endoxifen, the most active metabolite of the FDA-approved Selective Estrogen Receptor Modulator (SERM) tamoxifen, has shown promise in Phase 1 and small Phase 2 studies. Atossa's proprietary oral formulation of (Z)-endoxifen aims to bypass liver metabolism and stomach acid conversion, potentially offering a well-tolerated and effective option for breast cancer prevention and treatment.
This announcement is based on a press release statement from Atossa Therapeutics, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.